Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Ieq Capital LLC

Ieq Capital LLC lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) by 1,425.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 126,710 shares of the company’s stock after acquiring an additional 118,404 shares during the period. Ieq Capital LLC’s holdings in Apellis Pharmaceuticals were worth $4,043,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of APLS. Wolverine Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. True Wealth Design LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $56,000. KBC Group NV raised its holdings in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In other news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the completion of the transaction, the insider now owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Cedric Francois sold 2,824 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the transaction, the chief executive officer now directly owns 415,695 shares of the company’s stock, valued at approximately $12,271,316.40. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on APLS shares. Bank of America dropped their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and set a $26.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, January 29th. Oppenheimer dropped their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Thursday, February 13th. Finally, Citigroup dropped their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Get Our Latest Stock Report on Apellis Pharmaceuticals

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $27.52 on Friday. The company has a market cap of $3.42 billion, a P/E ratio of -13.56 and a beta of 0.96. The stock has a fifty day moving average price of $30.61 and a 200 day moving average price of $31.87. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90.

Apellis Pharmaceuticals Profile

(Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Read More

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.